Allergan Announces Death of Stephen J. Ryan, M.D.

Allergan Announces Death of Stephen J. Ryan, M.D.

Dr. Ryan Was Internationally Recognized Expert in Retinal Disease and Ocular Trauma and Member of the Allergan Board of Directors

IRVINE, Calif.--(BUSINESS WIRE)-- Allergan, Inc., (NYSE: AGN  ) today announced that Stephen J. Ryan, M.D., a member of the Allergan Board of Directors, died on April 29th,2013 after a short illness. Dr. Ryan was 72 years old.

“Steve, in all his modesty, was one of the greatest retinal surgeons and worldwide ophthalmic experts and, in fact, trained many of today’s global leaders in ophthalmology,” said David E.I. Pyott, Chairman, President, and Chief Executive Officer, Allergan. “As a member of the Allergan Board of Directors, Steve served the Company and the Board with unwavering loyalty and insight, and a commitment to corporate fiduciary duties, ethics and stewardship. As a scientific leader, he was passionate about sharing his knowledge and supporting Allergan’s R&D efforts to advance our robust pipeline and bring new therapies to market. During our many years of working together, I have valued Steve’s perspective and guidance. All of us who have had the privilege of working with Steve will miss him greatly, not only as a colleague, but as a friend.”

Dr. Ryan was an internationally recognized expert in the field of retinal disease and ocular trauma. Last year, Dr. Ryan was recognized as a Laureate of the American Academy of Ophthalmology, the Academy’s single highest honor and one that has been awarded to only a few individuals. Dr. Ryan served as President of the Doheny Eye Institute and as the Distinguished Grace and Emery Beardsley Professor of Ophthalmology at the Keck School of Medicine of the University of Southern California. He was the Dean of the Keck School of Medicine and Senior Vice President for Medical Care of the University of Southern California for 13 years and was also a long-standing member of the Institute of Medicine of the National Academy of Sciences. Dr. Ryan was the founding President of the National Alliance for Eye and Vision Research, and a member and director of the W.M. Keck Foundation and a member of the Arnold and Mabel Beckman Foundation.

Dr. Ryan joined the Allergan Board of Directors in 2002. During his tenure as a member of the Allergan Board of Directors, Dr. Ryan served as Chairman of the Board’s Science and Technology Committee and as a member of the Audit and Finance Committee. In January 2013, Dr. Ryan announced his retirement from the Allergan Board of Directors, effective at the annual stockholders’ meeting on April 30th, 2013.



Allergan Contacts:
Bonnie Jacobs, 856-912-9965; 714-246-5134; jacobs_bonnie@allergan.com
Cathy Taylor, 949-293-4453; 714-246-5551; taylor_cathy@allergan.com

KEYWORDS:   United States  North America  California

INDUSTRY KEYWORDS:

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2396681, ~/Articles/ArticleHandler.aspx, 10/31/2014 6:16:01 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...